Saturday 17 October 2026
Export HKPD’s income statement to Excel — free account
Cellyan Biotechnology Co., Ltd
HKPD Healthcare Medical Distribution
Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.
0.11
0.00
0.00%
Follow HKPD
| Older periods | Sep '24 | Mar '25 | Sep '25 | Mar '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | 0.00% | 0.00% | |
| — | — | 0.00% | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | 2.41 | 0.52 | 0.14 | |
Capital Expenditures |
— | (0.24) | (0.17) | (0.18) | |
| Other line items | |||||
Cash ROIC |
0.00% | 24.40% | 5.49% | 1.34% | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.98 | 1.97 | 1.02 | |
Capex/Depreciation |
— | (0.99) | (0.75) | (0.75) | |
Operating CF per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates